Recent Progress on the Molecular Aspects of Endocrine Tumors: Clinical Implications

Hormone Research in Paediatrics

Volumn 47, Issue 4-6, 1997, Pages 145-157

  Wynford Thomas, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Differentiation; Gsp; Oncogene; p53; Ras; Ret; Thyroid; Thyroid stimulating hormone; Tumour suppressor gene

Indexed keywords

THYROTROPIN RECEPTOR;

CARCINOGENESIS; CONFERENCE PAPER; DISEASE COURSE; EPITHELIUM TUMOR; GENE MUTATION; GENE TRANSFER; GENOTYPE; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; ONCOGENE RAS; ONCOGENE RET; PHENOTYPE; PRIORITY JOURNAL; THYROID FOLLICLE CELL; THYROID TUMOR; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

EID: 85025576916     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000185458     Document Type: Article

References (73)

1. Leblond CP: Classification of cell populations on the basis of their proliferative activity, Natl Cancer Inst Monogr 1964; 14:119-149.
2. Wrighl NA, Alison M: Biology of Epithelial Cell populations, Oxford, Clarendon Press, 1984, p 3.
3. Smith P, Wynford-Thomas D: Control of thyroid follicular cell proliferation: Cellular aspects: in Wynford-Thomas D, Williams ED (eds): Thyroid Tumours: Molecular Basis of Pathogenesis, Edinburgh, Churchill Livingstone, 1989, pp 66-90.
4. Coclet J, Foureau F, Kctelbanl P, Galand P, Dumont JE: Cell population kinetics in dog and human adult thyroid, Clin Endocrinol 1989:31:655-665.
5. Lcmoine NR, Wyllicr FS, Lillehaug JR, Stad-don SL, Hughes CM, Aasland R, Shaw J, Var-liaug IE, Brown CL, Gullick WJ, Wynford-Thomas D: Absence of abnormalities of the c-erb-l and c-crb-2 proto-oncogenes in human thyroid cnoplasia, Eur J Cancer 1990:26:777-779.
6. Wynford-Thomas D: Molecular genetics of thyroid cancer, Trends Endocrinol Metabol 1993:4:224-232.
7. Dumont JE, Lamy F, Roger P, Maenhaut C: Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotrophin and other factors, Phys Rev 1992: 72:667-697.
8. Parma J, Duprez L, Van Sande J, Cocliaux P, Gcrvy C, Mockel J, Dumont J, Vassart G: Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas, Nature 1993:365:649—651.
9. O'Sullivan C, Barton CM, Staddon SL, Brown CL., Lcmoine NR: Activating point mutations of the gsp oncogene in human thyroid adenomas, Mol Carcinogen 1991:4:345-349.
10. Suarez HG, du Villard JA, Caillou B, Schlum-bcrger M, Parmenticr C, Monier R: gsp mutations in human thyroid tumours, Oncogene 1991:6:677-679.
11. Wynford-Thomas D, Stringer BMJ, Williams ED: Dissociation of growth and function in the rat thyroid during prolonged goitrogcn administration, Acta Endocrinol 1982a: 101:210-216.
12. Michiels F, Caillou B, Talbot M, Dcssarps-Freichey F, Maunoury M, Schlumberger M, Merken L, Monier R: Oncogenic potential of guanine nucleotide stimulatory factor of subunit in thyroid glands of transgenic mice, Proc Natl Acad Sei USA 1994;91:10488-10492.
13. Ledent C, Dumont JE, Vassart G, Parmenticr M: Thyroid expression of an A2 adenosine receptor transgcne induces thyroid hyperplasia and hyperthyroidism, EMBO J 1992:1 1:537-542.
14. Wynford-Thomas D: In vitro models of thyroid cancer, Cancer Surv 1993:16:115-133.
15. Marshall CJ: Ras effectors, Curr Opin Cell Biol 1996:8:197-204.
16. Al-Alawi N, Rose DW, Buckmasicr C, Ahn N, Rapp U, Mcinkoth J, and Fcramisco JR: Thy-rotropin-induced mitogenesis is ras dependent but appears to bypass the Rat-dependent cytoplasmic kinase cascade, Mol Cell Biol 1995:15: 1162-1168.
17. Namba H, Rubin SA, Fagin JA: Point mutations of ras oncogencs are an early event in thyroid tumorigenesis, Mol Endocrinol 1990:4: 1474-1479.
18. Lcmoinc NR, Mayall IS, Wyllier FS, Williams Ed, Goyns M, Stringer B, Wynford-Thomas D: High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis, Oncogene 1989;4:159-164.
19. Said S, Schlumbcrgcr M, Suarez H: Oncogenes and anti-oncogenes in human epithelial thyroid tumours, J Endocrinol Invest 1994:17:371-379.
20. Lcmoinc NR, Staddon S, Bond J, Wyllic FS, Shaw JJ, Wynford-Thomas D: Partial transformation of human thyroid epithelial cells by mutant Ha-ras oncogene, Oncogene I990b:5: 1833-1837.
21. Bond JA, Wyliie FS, Rowson J, Radulcscu A, Wynford-Thomas D: In vitro reconstruction of tumour initiation in a human epithelium, Oncogene 1994:9:281-290.
22. Fusco A, Berlingicri MT, DiFiorc PP, Portella G, Grieco M, Veechio G: One- and two-step transformations of rat thyroid epithelial cells bv retroviral oncogcncs, Mol Cell Biol 1987:7: 3365-3370.
23. Rochefort P, Caillou B, Michiels F-M, Ledent C, Talbot M, Schlumberger M, Lavelle F, Mon-ier R, Feunteun J: Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter, Oncogene 1996:12:111-118.
24. Dawson TP, Radulcscu A, Wynford-Thomas D: Expression of mutant p2tras induces insu-lin-like growth factor I secretion in thyroid epithelial cells, Cancer Res 1995:55:915-920.
25. Ivan M, Eccles N, Wynford-Thomas D: Activated ras and ret oncogenes induce overexpression of The met receptor in human thyroid cells in vitro, EORTC-Thyroid Study Group Meeting, London, 1995.
26. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Mclillo R, Pierotti MA, Bon-garzone I, Della Porta G, Berger N, Peix JL, Paulin C, Fabien N, Vccchio G, Jenkins RB, Fusco A: Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype, J Clin Invest 1992:89:1517-1522.
27. Greco A, Pierotti MA, Bongarzone I, Pagliar-dini S, Lanzi C, Della Porta G: TRK-T1 is a novel oncogene formed by the fusion of TPR and TR.K genes in human papillary thyroid carcinomas, Oncogene 1992;7:237-242.
28. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A, Br J Cancer 1993; 363:458-460.
29. Wynford-Thomas D: Molecular genetics of thyroid cancer, TEM 1993:4:224—232.
30. Borrcllo MG, Pelici G, Ariglii E, De Filippis L, Greco A, Bongarzone I, Rizzctli MG, Pelicci PG, Pierotti MA: The oncogenic versions ofthe Ret and I rk tyrosine kinases bind She and Grb2 adaptor proteins, Oncogene 1994:9: 1661-1668.
31. Santoro M, Wong WT, Arqoca P, Eugenio S, Matoskova B, Gricgo M, Fusco A, Di Fiore PP: An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: Evidence for a re-specific signaling pathway, Mol Cell Biol 1994:14:663-675.
32. Santoro M, Mclillo RM, Grieco M, Berlingicri MT, Veechio G, Fusco A: The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line, Cell Growth Differ 1993:4: 77-84.
33. Harach HR, Franssila KO, Wascnius V-M: Occult papillary carcinoma of the thyroid, Cancer 1985:56:531-538.
34. Viglietto G, Chiapetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A: RET/ PTC oncogene activation is an early event in thyroid carcinogenesis, Oncogene 1995:11: 1207-1210.
35. Wright WE, Shay JW: Time, telomeres and tumours: Is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995; 5:293-297.
36. Bacchetti S, Counter CM: Telomeres and tel-omerase in human cancer, Int J Oncol 1995;7: 423-432.
37. Wynford-Thomas D: Does telomere shortening drive selection for p53 mutation in human cancer? Mol Carcinog 1995:12:119-123.
38. Pines J: Cydins and cyclin-dcpendent kinases: A biochemical view, Biochem J 1995:308:697- 711.
39. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin dependent kinases, Genes Dev 1995:9:1149-1163.
40. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen, Exp Cell Res 1994:211:90-98.
41. Votja PJ, Carl Barrett J: Genetic analysis of cellular senescence, Biochim Biophys Acta 1995: 1242:29-41.
42. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclinD/CDK4, Nature 1993:366:704-707.
43. Kamb A: Cell-cycle regulators and cancer, Trends Genet 1995;! 1:136-140.
44. Jones CJ, Shaw JJ, Wyllic FS, Gaillard N, Schlumberger M, Wynford-Thomas D: High frequency deletion of the tumour suppressor gcncP16INK4a(MTSl)in human thyroid cancer cell lines, Mol Cell Endocrinol 1996:116: 115-119.
45. Wynford-Thomas D: Thyroid cancer; in Le-moine E, Neoptolemos J, Cooke T (eds): Cancer: A Molecular Approach, Oxford, Blackwell, 1994, vol 12, pp 192-222.
46. Gumbiner BM: Cell adhesion: The molecular basis of tissue architecture and morphogenesis, Cell 1996:84:345-357.
47. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti F.: Dependence of cyclin E-CDK2 kinase activity on cell anchorage, Science 1996: 271:499-502.
48. Carcangiu ML, Steeper T, Zampi G, Rosai J: Anaplastic thyroid carcinoma, Am J Clin Pathol 1985;83:135-158.
49. Grccnblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumour suppressor gene: C'lucs to canccr etiology and molecular pathogenesis, Cancer Res 1994:54:4855-4878.
50. Ho T, Scyama T, Mizuno T, Tsuyama N, Hava-shi T, Hayashi Y, Dohi K, Nakamura N, Akiyama M: Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland, Cancer Res 1992;52:1369-1371.
51. Matias-Guiu X, Cuatreeasas M, Musulen E, Prat J: p53 expression in anaplastic carcinomas arising from thyroid papillary carcinoma, J Clin Pathol 1994:47:337-339.
52. Donghi R, Longoni A, Pilolti S, Michieli P, Della Porta G, Pierotti MA: Gene p53 mutations arc restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland, J Clin Invest 1993:91:1753-1760.
53. Wvllie F, Lcmoinc N, Barton C, Dawson T, Bond J, Wynford-Thomas D: Direct growth stimulation of normal human epithelial cells by mutant p53, Mol Carcinog 1993:7:83-88.
54. Wyllic FS, Haughlon MF, Blaydes JP, Schlum-bcrger M, Wynford-Thomas D: Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cclls, Oncogene 1995:10:49—59.
55. Battista S, Martclli ML, Fedele M, Chiappetta G.Trapasso F, Dc Vita G, Battaglia C, Santoro M, Viglietto G, Fagin JA, Fusco A: A mutated p53 gene alters thyroid cell differentiation, Oncogene 1995:11:2029-2037.
56. Wynford-Thomas D, Bond JA, Wyllic FS, Burns JS, Williams ED, Jones T, Sheer D, Lemoinc NR: Conditional immortalisation of human thyroid epithelial cells: A tool for analysis of oncogene action, Mol Cell Biol 1990:10: 5365-5377.
57. Bond JA, Ness GO, Rowson J, Ivan M, White D, Wynford-Thomas D: Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: An cpi-gcnetic mechanism of tumour progression? Int J Cancer, in press.
58. Bond JA, Wyllic FS, Ivan M, Dawson T, Wyn-ford-Thomas D: A variant epithelial subpopulation in normal thyroid with high proliferative capacity in vitro, Mol Cell Endocrinol 1993:93: 175-183.
59. Ledent C, Dumont J, Vassart G, Parmcntier M: Thyroid adenocarcinomas secondary to tissue-specific expression of simian Virus-40 large T-antigen in transgenic mice, Endocrinology 1991:129:1391-1401.
60. Lcdcnt C, Marcotte A, Dumont JE, Vassart G, Parmcntier M: Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene, Oncogene 1995; 10:1789-1797.
61. Bongarzone I, Pierotti MA, Monzini N, Mon-dcllini P, Manenti G, Donghi R, Pilotti S, Grie-co M, Santoro M, Fusco A, Vecchio G, Della Porta G: High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma, Oncogene 1989:4:1457-1462.
62. Butti MG, Bongarzone I, Ferraresi G, Mondcl-lini P, Borrello MG, Picrotti MA: A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRKI genes producing TRK oncogenes in papillary thyroid carcinomas, Genomics 1995:28:15- 24.
63. Greco A, Picrotti MA, Bongarzone I, Pagliar-dini S, Lanzi C, Della Porta G: TRK-T1 is a novel oncogene formed by the fusion of TPR and TR K genes in human papillary thyroid carcinomas, Oncogene 1992;7:237-242.
64. Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, Picrotti MA: The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain, Mol Cell Biol 1995; 15:6118-6127.
65. Picrotti MA, Santoro M, Jenkins RB, Sozzi G, Bongarzone I, Grieco M, Monzini N, Miozzo M, Herrmann MA, Fusco A, Hay ID, Della Porta G, Vecchio G: Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC, Proc Natl Acad Sci USA 1992:89:1616-1620.
66. Grieco M, Ccrrato A, Santoro M, Fusco A, Melillo RM, Vecchio G: Cloning and characterisation of H4 (D10S170), a gene involved in RET rearrangements in vivo, Oncogene 1994; 9:2531-2535.
67. Tong Q, Li Y, Smanik PA, Fithian U, Xing S, Mazzaferri EI, Jhiang SM: Characterisation of the promoter region and oligomerization domain of H4 (DI OS 170), a gene frequently rearranged with the ret proto-oncogene, Oncogene 1995;10:1781-1787.
68. Bongarzone I, Monzini N, Borrello MG, Carca-no C, Ferrarcsi G, Arighi E, Mondcllini P, Della Porta G, Picrotti MA: Molecular characterisation of a thyroid tumour-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit Rla of cyclic AMP-dependent protein kinase A, Mol Cell Biol 1993;13:358-366.
69. Sozzi G, Bongarzone I, Miozzo M, Borrello MG, Butti MG, Piloni S, Della Porta GD, Pie-rotti MA: A 1(10:17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma, Genes C'hromo-som Cancer 1994:9:244-250.
70. Santoro M, Dathan NA, Bcrlingicri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchi G, Fusco A: Molecular characterisation of RET/PTC3: A novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma, Oncogene 1994:9:509-516.
71. Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondcllini P, Pilotti S, Fusco A, Della Porta G, Picrotti MA: Frequent activation of ret proto-oncogene by fusion with a new activating gene in papillary thyroid carcinomas, Cancer Res 1994:54:2979-2985.
72. Minoletti F, Butti MG, Coronelli S, Miozzo M, Sozzi G, Piloni S, TunnaclilTc A, Picrotti MA, Bongarzone I: The two genes generating RET/ PTC3 arc localized in chromosomal band lOql 1.2, Genes Chromosom Cancer 1994:11: 51-57.
73. Yuspa SI I: The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis, Canccr Res 1994:54:1178-1189.